Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rocket Lab USA Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Rocket Lab USA Inc trades at $80.29 (market cap $50.64B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RKLB | |
|---|---|---|
Market Cap | $39.89B | $50.64B |
Sector | Health | Technology |
52-Week High | $491.22 | $150.23 |
52-Week Low | $278.09 | $39.03 |
Enterprise Value | $38.15B | $49.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Rocket Lab (RKLB) trades at $81.04, down 1.83% amid broader space sector weakness. The stock shows bearish technical signals with support at $77-$81 levels, while fundamentals reveal strong revenue growth ($602M in 2025) but persistent losses (-$198M net income). Recent news highlights the $8B Iridium acquisition and innovative 'Hungry Hippo' technology, positioning the company for long-term growth in the expanding space economy.
Analyst consensus remains bullish with a $119.10 price target (75% buy ratings), though profitability challenges and high valuations (P/S 66.26) present near-term risks. The company's expansion into satellite communications and defense contracts provides growth catalysts, but investors face volatility from sector-wide valuation concerns and execution risks on major acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
